I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
|
|
- Johnathan Green
- 5 years ago
- Views:
Transcription
1 I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane
2 What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable to age-matched population
3 ??? Medium-term Results of Imatinib Treatment in CML 100 IRIS Trial Update: the 8-Year Overall Survival 80 OS (%) Estimated OS at 8 yrs: 85% (93% considering only CML-related deaths) Mos Since Randomization Deininger M, et al. ASH Abstract 1126.
4 Overall outcome of TKI treatment in CML ENESTnd + DASISION, 4 years data NILO+DASA vs IMATINIB p No. of pts Still on treatment 66% 61% Cum. prob. of MR % 58% <0.001 Cum. prob of MR % 29% <0.001 Progression # 6.8% 7.6% PFS 91% 91% AP/BP (transformation) 3.9% 7.4% 0.04 Death 6.3% 7.4% Overall survival 93% 92% # ENESTnd: AP, BP, death due to any cause at any time DASISION: rising WBC count, loss of CHR, loss of MCyR, CCA/Ph+, AP, BP
5 Loss in life expectancy of patients with CML in Sweden, over year of diagnosis, by age at diagnosis and sex
6 The goals of CML management in 2018 Life expectancy: Normal Optimal response (ELN 2013), MR 3.0 or better? Quality of live: Normal Select treatment for side effects, comorbidities, complications Cure: Treatment-free remission Test and select treatment for deep molecular response
7 The concept of CML eradication (and its immunogenicity) Three decades of transplantation for CML Survival of 173 patients allo-allografted from 2000 to 2010 stratified by EBMT risk score Jirí Pavlu, Blood. 2011;117(3):
8 Donor lymphocyte infusion for relapsed CML after SCT Chalandon et al BMT (2010) 45,
9 History of treatment discontinuation Successful discontinuation examples already in the IFN era - 22 of 44 patients in CCR stopped treatment successful (Bonifazi F. et al., Blood 2001) - 7 of 15 patients in CCR stopped treatment successful (Mahon FX. et al., JCO 2002) - 39 of 140 patients in CCR kept response without treatment for a median of 50 months (Kantarjian H. et al.,cancer 2003) First case reports with TKI treatment already in 2004 (Mauro M. et al., Leuk Res 2004) Pilot study with 12 patients in 2007 (Rousselot P. et al., Blood)
10 STIM1 Study Design Start Imatinib CMR Sustained CMR for 2 y STOP IMATINIB N = 100 TFR 5 RQ-PCR assessments during these 2 y RQ-PCR every month in the first year and every 2 mo thereafter Sixth data point checked in centralized laboratory Response required to attempt TFR: Sustained CMR (no detectable BCR-ABL1 for 2 consecutive years with 5 RQ-PCR assessments), confirmed in a central laboratory with a sensitivity of > 4.5 logs Molecular relapse: Confirmed BCR-ABL1 transcript positivity in 2 consecutive RQ-PCR assessments with a 1-log increase in the second assessment relative to the first, or loss of MMR in 1 assessment CMR, complete molecular response; MMR, major molecular response (BCR-ABL1 0.1% on the International Scale [IS]); RQ-PCR, real-time quantitative polymerase chain reaction; STIM1, Stop Imatinib 1 TFR study. 1. Mahon FX, et al. Lancet Oncol. 2010;11: Mahon FX, et al. Blood. 2013;122(21) [abstract 255]. 3. Etienne G, et al. Blood. 2015;126(23) [abstract 345].
11 STIM 1: Molecular Recurrence-Free Survival (N = 100) The median molecular follow-up after treatment discontinuation is 77 months (range, 9 to 95 months). Etienne G, et al. ASH Abstract 345.
12 Kaplan-Meier probability of CMR after discontinuation of Imatinib in 100 CML patients By SOKAL score Among the 11 patients with high Sokal Risk score 9 relapsed
13 Kaplan-Meier probability of CMR after discontinuation of Imatinib in 100 CML patients By sex
14 Kaplan-Meier probability of CMR after discontinuation of Imatinib in 100 CML patients By previous treatment
15 Kaplan-Meier probability of CMR after discontinuation of Imatinib in 100 CML patients By duration of Imatinib treatment
16 ( Imatinib discontinuation studies Study N Treatment before discontinuation Response Required to Stop Therapy Definition of relapse TFR (different FU) STIM IFN then lmatinib for 3 years CMR Loss of MMR or 1-log increase in BCR-ABL 39 % STIM lmatinib for 3 years As for STIM As for STIM 46 % ALLG CML8 40 lmatinib for 3 years UMRD 2 years Loss of MMR or confirmed loss of MR % According to STIM 80 lmatinib for 3 years As for STIM; occasional positive samples eligible Loss of MMR 64 % EUROSKI 868 Imatinib, Dasatinib, Nilotinib MR 4 for 1year; TKI for 3 years Loss of MMR 54 % ISTAV 112 lmatinib Undetectable PCR (3 PCRs) Loss of MMR 52% DESTINY 168 Imatinib, Dasatinib, Nilotinib MR 4 and stable response under half standard dose for 12 months Loss of MMR In progress
17 ( 2 -G TKI discontinuation studies Study N Treatment before discontinuation Response Required to Stop Therapy Definition of relapse TFR (different FU) STOP 2G-TKI pilot 50 Nilotinib or Dasatinib CMR for median 29 mo. Loss of MMR 61% ENEST freedom 175 Nilotinib MR 4.5 for 1year Loss of MMR 51.6% ENESTop 117 Nilotinib MR 4.5 for 1year Confirmed loos of MR 4.0 or any loss of MMR 58.7% ENESTpath 650 Nilotinib Randomized MR 4.5 for 1year vs 2year Confirmed loos of MR 4.0 or any loss of MMR In progress ENESTGoal 300 Nilotinib MR 4.5 for 1year Confirmed loos of MR 4.0 or any loss of MMR In progress DASFREE 75 Dasatinib MR 4.5 for 1year Loss of MMR In progress DADI 63 Dasatinib DMR for 1year Loss of MMR 48%
18 Prognostic factors of TFR in TKI discontinuation studies Factor category Factors Prognostic value Patient Age, Sex No Disease Prognostic score at diagnosis Non high risk sokal best (Imatinib) Type of TKI No comparative studies Treatment history and response to therapy History of suboptimal response or resistance TKI treatment duration (total) Deep molecular response duration Depth of deep molecular response (MR4.0, MR4.5 or even deeper) Decreased TFR probability Imatinib: yes Dasatinib or Nilotinib: not studied yet Imatinib: yes Dasatinib or Nilotinib: not studied yet Difficult to assess with current RT- QPCR techniques
19 Randomized comparative prospective studies in CML Treatment Study Response Survival TFR IMA 800 vs IMA 400 GERMANY CML IV + = NA IMA 800 vs IMA 400 GIMEMA = = NA IMA 800 vs IMA 400 TOPS = = NA NIL vs IMA 400 ENESTnd + = NA DAS vs IMA 400 DASISION + = NA BOS vs IMA 400 BFORE + NY NA NIL vs IMA NIL SUSTRENIM (GIMEMA / HOVON) NY NY NY IFN+IMA vs IMA 400 GERMANY CML IV = = NA IFN+IMA vs IMA 400 FRENCH SPIRIT + = NA IFN+IMA vs IMA 400 NORDIC + NA NA NILO+IFN vs NILO TIGER NY NY NY DAS+IFN vs DAS NORDIC/FRANCE + NA NA BOS+IFN vs BOS NORDIC/FRANCE NY NY NY
20 Deep Molecular Response Issues relevant for a TFR trial Stability of response (sustained response) Need for reproducibility at RQ-PCR low levels NGS vs Digital PCR Sensitivity (4.0 vs 4.5 vs Better?) Need for sensitive techniques Digital PCR vs Genomic DNA PCR vs NGS-based methods Quantitation of Ph+ Stem cells?
21 Hypothetical Model of CML persistence and recurrence versus extinction The eradication of the leukemic clone may depend on inherent features of the disease or on the duration of therapy, or both. Deininger, M. Nat. Rev. Clin. Oncol. 2011
22
23 Lessons learned from discontinuation trials Patients who discontinued treatment still have residual Ph positive cells left as indicated by genomic PCR data (Ross et al Blood 2013) Fluctuating levels of residual disease often observed in patients after treatment discontinuation Does immune system play a role in CML control?
24 Cancer immunoediting Immune system dysfunctional (anergic) in many cancer types In CML: Leukemia specific T- cells exhausted High levels of PD1 on CD8 cells (Mumbrect et al, Blood 2009; Christiansson et al PlosOne 2013) Quantitative and qualitative defects in NKcells (Chen et al, Leukemia 2011) Can the function of immune system be restored in CML?
25 TKI Induced Immunomodulation Tyrosine kinase inhibitors are not entirely selective; effects on cells other than the malignant target cell lnhibition of functionally important kinases in normal cells eg. 2nd generation TKI Dasatinib inhibits many kinases important in immune responses (T- and B-cell activation and proliferation) Imatinib Nilotinib Dasatinib
26 Discontinuation of IFN monotherapy IFN discontinuation(ifn monotherapy) Most patients have molecular evidence of MRD despite of successful discontinuation Patients who have achieved good response to IFN-a and have been able to stop the therapy, have Increase in NK-cell number Clonal γ/δ T-cells and a unique cytokine profile Increased CD8+ central and CD4+ effector memory pool and secretion of Th1 inflammatory cytokines Kreutzman A et al., PloS ONE 2011;6(8):e23022 llander et al, PLoS One Jan 31;9(1):e8n 94
27 Imunological studies in TKI stopping trials
28 Imunological studies in TKI stopping trials NK cells: Effector cells? Modulator of CTL or other effector immune cell response? Only a marker?
29 Role of NK cells in tumor immunology
30 Moving TFR into clinical practice in CML Hughes TP, Ross DM. Blood 2016
31 Treatment free remission Key issues remain under investigation Optimal frontline treatment strategy to achieve TFR Ideal duration of TKI therapy prior discontinuation Ideal depth and duration of molecular response Ideal criteria for reinitiating therapy Predictive factors for achieving deep molecular response Predictive factors for remaining in remission upon treatment discontinuation
32 The Molecular Response Measuring BCR-ABL transcript levels - Methods, standardization - Which levels are important? - At what time are important?
33 Molecular Response Definitions (MolR) RQ-PCR: BCR-ABL/control gene - Blood, 20mL, buffy-coat - International scale (IS) New Old BCR-ABL/ABL IS Abl copies MR3.0 Major (MMolR) 0.1% >10,000 MR % (or Undetect) >10,000 MR4.5 Complete (CMolR) % (or Undetect) >32,000 MR % (or Undetect) >100,000
34 OS according to BCR-ABL months 4 years survival, 93% 8 years survival < % % % 0.1 1% > 1% Survival probability All pa:ents with primary ima:nib, n = 1194 BCR-ABL IS 8-y survival p-value < % 92% n.s. n.s % 90% n.s. n.s % 88% 0.1 1% 83% n.s. n.s. > 1% 78% Years a.er diagnosis Pa#ents at risk: < % % % % > 1%
35 Level of MRD vs time of treatment: the EURO-SKI trial Saussele s. et al. Lancet Oncolgy 2018
36 The concept of deep molecular response
37 It is possible to predict Deep Molecular remission during the first months of treatments?
38 The BCR-ABL transcripts level at 3 mo. (10%) may have a prognostic value Marin D et al., J Clin Oncol., 2012; 30: Hanfstein B et al., Leukemia. 2012; 26:
39 Proportion of Patients With MR 4.5 by BCR-ABL Levels at 3 Months Nilotinib 300 mg BID BCR-ABL IS 1%: 56% of pts Imatinib 400 mg QD ENESTnd 5-Year Update BCR-ABL IS 1%: 16% of pts Patients With MR 4.5, % BCR-ABL Level 1% > 1% to 10% > 10% Pts MR 4.5 by 5 Years a MR 4.5 by 4 Years a 70% 58% P = % P = % P =.0001 P = % 8% Patients With MR 4.5, % BCR-ABL Level 1% > 1% to 10% > 10% Pts MR 4.5 by 5 Years a MR 4.5 by 4 Years a 67% 65% P =.0001 P < % 24% P =.0016 P = 15% % Time Since Randomization, Calendar Years Time Since Randomization, Calendar Years! Patients with BCR-ABL 1% at 3 months have significantly higher rates of MR 4.5 by 5 years! More patients achieve BCR-ABL 1% at 3 months on nilotinib 300 mg BID vs imatinib Data cutoff: May 22, 2013 Saglio G, et al. Blood. 2013:[abstract 92]. a Cumulative response rates reported consider each year to consist of twelve 28-day cycles.
40 DASISION 3-year update MR 4.5 According to BCR-ABL Level at 3 Months Dasatinib 100 mg QD 84% of patients had 10% BCR-ABL 48% of patients had 1% BCR-ABL Imatinib 400 mg QD 64% of patients had 10% BCR-ABL 13% of patients had 1% BCR-ABL 100 BCR-ABL level at 3 months 3-Year MR BCR-ABL level at 3 months 3-Year MR 4.5 Patients with MR 4.5 (%) % 37.5% } P<.0001 >1-10% 14.0% } P=.0380 >10% 2.7% 10% vs >10% P= % vs >1% P< % 43.8% } P<.0001 >1-10% 11.5% } P=.0204 >10% 2.4% 10% vs >10% P= % vs >1% P< Months Months Saglio G. et al., Blood 2012:[abstract 1675].
41 Imprecision of QPCR assays of CML mass Courtesy from S Branford
42 Putting CML response into perspective International Standard (IS) qpcr Early Molecular Response: <10% or 1-log (10x) drop from starting level 10% Early Molecular Response Early Molecular Response Complete Cytogenetic Response: <1% or 2-log (100x) drop 1% Complete Cytogenetic Response Complete Cytogenetic Response Major Molecular Response: <0.1% or 3-log (1000x) drop 0.1% Major Molecular Response Major Molecular Response 4-log drop (<0.01%) 4.5 log drop, MR4.5, Complete Molecular Remission: <0.0032%; below the level of detection for standard labs 0.01% % MR5-6? MR4 MR4.5 CMR MR4 MR4.5 CMR Inverted iceberg schematic of CML response over time. Adapted from Mauro MJ. Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much? Hematology Am Soc Hematol Educ Program. 2014
43 Early kinetics of response: the halving time Patients with BCR-ABL values months had better outcomes if the BCR-ABL halving time was <76 days
44 SUSTRENIM Study Study Design
45 Conclusions Is it possible to cure CML patients without Allo- SCT? Yes, but. How many patients? Which treatment? QoL improvement?
46 Thank you for the attention!
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationDati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationTreatment free remission in CML: from the concept to practice. François-Xavier Mahon. Cancer Center Bordeaux Université Bordeaux, France
Treatment free remission in CML: from the concept to practice François-Xavier Mahon Cancer Center Bordeaux Université Bordeaux, France CML is a model 1960 1970 1980 1990 2000 2010 Philadelphia chromosome
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationNEW DRUGS IN HEMATOLOGY
NEW DRUGS IN HEMATOLOGY BOLOGNA, 15-17 April 2013 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA MICHELE BACCARANI michele.baccarani@unibo.it Historic Development of CML Therapy Palliative Therapy
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationTreatment free remission 2016
Treatment free remission 2016 Pr Ph Rousselot Université de Versailles Saint-Quentin-en-Yvelines Hôpital André Mignot, Hôpitaux de Versailles, France How many patients still on imatinib? Versailles cohort
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationStopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus Frankfurt I 27.5.2017 Aims of CML Therapy Leukemia cells >10 12 CHR 10
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationAGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA.
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA Michele.Baccarani@unibo.it EUROPEAN LEUKEMIANET 2013 (Blood 2013;122:885 892). RESPONSE
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationDeep molecular responses for treatment- free remission in chronic myeloid leukemia
Cancer Medicine REVIEW Open Access Deep molecular responses for treatment- free remission in chronic myeloid leukemia Stéphanie Dulucq 1 & Francois-Xavier Mahon 2 1 Laboratoire d Hématologie, Centre Hospitalier
More informationCML: Role of combination treatments, Interferon and immunotherapy in CML
CML: 2017 Role of combination treatments, Interferon and immunotherapy in CML Andreas Burchert Philipps Universität Marburg Universitätsklinikum Gießen und Marburg GmbH Key Developments that will Change
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationDoes Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationESMO Updated Guidelines & Treatment Strategies in CML-CP: Maximizing Eligibility for TFR.
ESMO Updated Guidelines & Treatment Strategies in CML-CP: Maximizing Eligibility for TFR. Pierre Laneuville, MD, FRCP(C) McGill University Health Center, Montreal. Korea, March 2018. Disclosures Activity
More informationImatinib dose intensification, combination therapies. Andreas Hochhaus Universitätsklinikum Jena, Germany
Imatinib dose intensification, combination therapies Andreas Hochhaus Universitätsklinikum Jena, Germany Apperley JF. Lancet Oncol. 2007 High OCT-1 activity is associated with faster MMR in imatinib treated
More information1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with
1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with both Nilotinib and Dasatinib. Nilotinib for the cardio
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationAccepted Manuscript. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. Pradnya Chopade, Luke P.
Accepted Manuscript Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors Pradnya Chopade, Luke P. Akard PII: S2152-2650(18)30343-4 DOI: 10.1016/j.clml.2018.06.029
More informationNEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT Michele.baccarani@unibo.it Michele BACCARANI, MD Professor of Hematology at the Universities of Trieste,
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More informationPost ASH Actualités LMC
Post ASH 2014 - Actualités LMC Actualités de première ligne LMC PC ENESTnd (6 ans) Dasision (5 ans) EPIC Spirit France (5 ans) Spirit 2 UK (5 ans) ENESTnd: Mise à jour à 6 ans Design = 846 ults with wly
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationMilestones and Monitoring
Curr Hematol Malig Rep (2015) 10:167 172 DOI 10.1007/s11899-015-0258-1 CHRONIC MYELOID LEUKEMIAS (E JABBOUR, SECTION EDITOR) Milestones and Monitoring Alessandro Morotti 1 & Carmen Fava 1 & Giuseppe Saglio
More informationJuan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
Juan Luis Steegmann Hospital de la Princesa. Madrid. Juan Luis Steegmann Hospital de la Princesa. Madrid No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationWhen to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany
When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 μ -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl
More informationWhat is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas
What is New in CML 2018 Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas Final Results CML-IV Molecular Response with Imatinib 1538 pts newly
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More informationCML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationDiscontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM
Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM François-Xavier Mahon, Delphine Réa, Joëlle Guilhot, François
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationStudy Design and Endpoints
Complete Molecular Response (CMR) Rate With Nilotinib in Patients With CML-CP Without CMR After 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial Timothy P. Hughes, Jeffrey H.
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationImatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
More information1794 Updating Long-Term Outcome of Intermittent Imatinib. (INTERIM) Treatment in Elderly Patients with Ph+-CML
738 What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) after Imatinib Loses Patent Exclusivity? https://ash.confex.com/ash/2014/webprogram/paper71699.html
More informationCML Update 2016 Arthur 2016
CML Update 2016 Chronic Myeloid Leukemia Splenomegaly CML (3 phase disease) Increased white cells Malignant proliferation of myeloid white cells Initially mature cells a) chronic phase of disease Evolution
More informationChronic Myeloid Leukemia Outlook: The Future of CML Therapy
Chronic Myeloid Leukemia Outlook: The Future of CML Therapy Neil Shah, MD PhD Edward S. AgenoDistinguished Professor in Hematology/Oncology UCSF School of Medicine San Francisco, California Progression
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationRecent advances in the path toward the cure for chronic myeloid leukemia
VOLUME 46 ㆍ NUMBER 3 ㆍ September 2011 THE KOREAN JOURNAL OF HEMATOLOGY REVIEW ARTICLE Recent advances in the path toward the cure for chronic myeloid leukemia Dong-Wook Kim Department of Hematology, Seoul
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationMolecular monitoring in chronic myeloid leukemia how low can you go?
CHRONIC MYELOID LEUKEMIA Molecular monitoring in chronic myeloid leukemia how low can you go? Susan Branford Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide,
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds UT Southwestern October 28, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal
More informationCHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It
CHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It Jeffrey H Lipton PhD MD Princess Margaret Cancer Centre Professor of Medicine University of Toronto CAGPO Annual Conference St. John
More informationGoals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?
MINIMAL RESIDUAL DISEASE:CHRONIC MYELOID LEUKEMIA AND ACUTE LYMPHOCYTIC LEUKEMIA Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much? Michael J. Mauro 1 1 Memorial
More informationPatient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
VOLUME 32 NUMBER 5 FEBRUARY 10 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Patient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
More informationDose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus Hadera I Oct 2018 Front-line Randomized Trials in CML-CP Trial Drugs References IRIS IM 400 vs IFN/AraC TOPS IM
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationDiagnosis and Management of Chronic Myeloid Leukaemia
Diagnosis and Management of Chronic Myeloid Leukaemia Dr Simon Watt Dr Katherine O Neill Dr Fiona Dignan Written July 2017 Prof Tim Somervaille Review July 2019 1 Table of Contents 1.0 Introduction 3 2.0
More informationMP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
Medical Policy BCBSA Ref. Policy: 2.04.85 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 8.01.30 Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More information517 Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML
517 Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML https://ash.confex.com/ash/2014/webprogram/paper66809.html Objective. SPIRIT 2 is the largest
More informationDiscontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping?
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping? David Pham, PharmD PGY2 Hematology/Oncology Pharmacy Resident South Texas VA Health Care System
More information9/26/2018. Learning Objectives
ADVANCES IN CHRONIC MYELOID LEUKEMIA Alison Wakoff Loren, MD, MSCE Associate Professor of Medicine Director, Blood & Marrow Transplantation Vice Chair, Faculty Development Department of Medicine Perelman
More informationPost-ASH 2015 CML - MPN
Post-ASH 2015 CML - MPN Fleur Samantha Benghiat, MD, PhD Hôpital Erasme, Brussels 09.01.2016 1. CML CML 1st line ttt Prognosis Imatinib Nilotinib Response Discontinuation Dasatinib Low RISK PROFILE High
More informationMolecular monitoring in CML and the prospects for treatment-free remissions
MANAGING TYPICAL AND ATYPICAL CHRONIC MYELOID LEUKEMIA Molecular monitoring in CML and the prospects for treatment-free remissions Michael W. Deininger 1,2 1 Huntsman Cancer Institute, The University of
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationWhat Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM
Welcome to Master Class for Oncologists Session 2: 8:15 AM - 9: AM Miami, FL December 18, 29 Chronic Myelocytic Leukemia: Imatinib and Beyond Speaker: Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds Hackensack, ew Jersey September 22, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course
More informationCML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008
Novità dall EHA >> [ Leucemia mieloide cronica ] CML EHA: what s new? Relatore: G. MARTINELLI 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia mieloide cronica - Copyright FSE 1 CML EHA:
More informationHSCT for Myeloproliferative Disorders. Jane Apperley
HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationCurrent State of CML Management. Phillip le Coutre, MD Charité-University Medicine Berlin Berlin, Germany
Current State of CML Management Phillip le Coutre, MD Charité-University Medicine Berlin Berlin, Germany 1845 R. Virchow J. Bennett Berlin Edinburgh Geary CG. Br J Haematol. 2000;110(1):2-11. QoL, quality
More informationUpdated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
For reprint orders, please contact: reprints@futuremedicine.com Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia Nilotinib,
More informationGreater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012
Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012 Dr Simon Watt Dr Shiva Natarajan 1.0 Introduction The landscape in chronic myeloid leukaemia (CML) has changed dramatically
More information